Observational studyBritish journal of haematology2026
Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study.
Abstract readObservational Study
In one paragraph
Observational study in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors.
Yolanda BenaventeUnit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain.
Sara HermosaUnit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain.
Nikos PapadimitriouNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.
Alyssa Clay-GilmourDepartment of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
Elizabeth E BrownDepartment of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0003-4498-7858
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Qing LanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Mark PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-6538-9705
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Parveen BhattiDivision of Population Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Wendy CozenDivision of Hematology-Oncology, Department of Medicine, University of California Irvine, Orange, California, USA.
Aaron NormanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Susan L SlagerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-5173-4712
James R CerhanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7482-178X
Vincent RajkumarDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-5862-1833
Shaji K KumarDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Celine M VachonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Anne J NovakDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7904-1651
Thomas M HabermannDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-3532-9132
Brian K LinkDepartment of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
Gilles SallesDepartment of Medicine, Memorial Sloan Kettering Cancer and Weill Cornell Medical College, New York, New York, USA.ORCID https://orcid.org/0000-0002-9541-8666
Herve GhesquieresDepartment of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.
Paige M BracciDepartment of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.
Elizabeth HollyDepartment of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.
Rosalie G GriffinDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michelle A T HildebrandtDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-6769-6872
Roel C H VermeulenInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
P Martijn KolijnInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Henrik HjalgrimHaematology, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
Karin Ekström SmedbyDepartment of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden.
Harindra JayasekaraCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-2453-0183
Simon CheahCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0352-1165
Alain MonnereauEpidemiology of Childhood and Adolescent Cancers Group, Inserm, Center of Research in Epidemiology and Statistics Sorbonne, Paris, France.
Yu ChenNYU Grossman School of Medicine, New York, New York, USA.
Alan ArslanNYU Grossman School of Medicine, New York, New York, USA.
Yawei ZhangDepartment of Cancer Prevention and Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Nicola J CampHuntsman Cancer Institute and Division of Hematology and Hematological Malignancies, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Douglas W SborovHuntsman Cancer Institute and Division of Hematology and Hematological Malignancies, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Afaf E G OsmanHuntsman Cancer Institute and Division of Hematology and Hematological Malignancies, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Elad ZivDepartment of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Immaculata De VivoChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Vijai JosephNiehaus Center for Inherited Cancer Genomics and Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lauren R TerasDepartment of Population Science, American Cancer Society, Atlanta, Georgia, USA.
Alpa V PatelDepartment of Population Science, American Cancer Society, Atlanta, Georgia, USA.
Eleanor KaneEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.ORCID https://orcid.org/0000-0002-7438-9982
Claire M VajdicKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Adrien GuilloteauRegistre des Hémopathies Malignes de Côte d'Or, Dijon, France.ORCID https://orcid.org/0000-0003-1161-297X
Pierluigi CoccoCentre for Occupational and Environmental Health, Division of Public Health, Health Services Research Primary Care, University of Manchester, Manchester, UK.
Laia AlemanyUnit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain.
Juan SainzCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
James McKayIARC, Lyon, France.
Brenda M BirmannChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Delphine CasabonneUnit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain.ORCID https://orcid.org/0000-0002-7874-3707
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MBIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3MGenome-Wide Association Study of Endometrial CancerR01CA134958 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI DE VIVO, IMMACULATA · 2009 to 2010
$4.3MRisk factors for molecular subtypes of NHL a prospective evaluationR01CA202712 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BIRMANN, BRENDA M, WANG, SOPHIA S. · 2016 to 2020
$3.7MA prospective analysis of peripheral blood cytokines and non-Hodgkin lymphomaR01CA149445 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M · 2011 to 2015
$3.0MExposure to Organochlorines, EBV, and the Risk of NHLR01CA098122 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI LADEN, FRANCINE · 2003 to 2006
$2.1MCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP) CB06/02/0073European Regional Development Fund (FEDER)Fundacio Institucio dels Centres de Recerca de Catalunya (CERCA) Program / Generalitat de CatalunyaInstituto de Salud Carlos III FI21/00090Instituto de Salud Carlos III PI20/00288Instituto de Salud Carlos III PI20/01845Instituto de Salud Carlos III PI25/00156NCI NIH HHS NCI/U01CA257679NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA098122NCI NIH HHS R01 CA134958NCI NIH HHS R01 CA149445NCI NIH HHS R01 CA202712NCI NIH HHS UM1 CA186107The Agency for Management of Universities and Research Grants (AGAUR) 2014SGR756The Agency for Management of Universities and Research Grants (AGAUR) 2021SGR01354The Consejería de Salud y Familia de la Junta de Andalucía PY20/01282
Abstract
Evidence for an association between insulin-like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF-I concentrations and risk of MM by combining baseline serological data among UK Biobank participants (n = 444 187; 732 incident MM) with a two-sample Mendelian randomisation (MR) analysis using identified genetic variants associated with circulating total IGF-I and IGF-binding protein 3 (IGFBP-3) in the InterLymph consortium (2434 MM and their 2567 controls). Finally, additional lymphoid neoplasm (LN) subtypes were included for comparison with the main hypothesis. Circulating IGF-I level was positively associated with MM risk Hazard ratio-HR-per one standard deviation-SD-increase (HR
Indexed as
Insulin-Like Growth Factor IMultiple MyelomaAgedFemaleHumansInsulin-Like Growth Factor Binding Protein 3MaleMendelian Randomization AnalysisMiddle AgedPolymorphism, Single NucleotideRisk FactorsIGF1 protein, humanIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIGFBP‐3IGF‐Ilymphoid neoplasmsMendelian randomisationmultiple myelomaserum
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.